[Evaluation of the effectiveness of a new myorelaxant nimbex (cisatracurium besilate) in children].
Cisatracurium besilate was used in 21 children aged 2-12 years (ASA classes I-II) for intravenous anesthesia anesthetic + nitrous oxide + oxygen (group 1, 11 pts) and halothane + nitrous oxide + oxygen (group 2, 11 pts). In group 1 the initial nimbex dose was 0.15 mg/kg, in group 2 0.12 mg/kg, which created good or excellent conditions for intubation within 2 min and induced a neuromuscular blocking (NMB) for 44.2 +/- 4.7 and 37.6 +/- 5.9 min, respectively. NMB was maintained by bolus injections of nimbex in doses of 0.03 mg/kg (group 1) and 0.02 mg/kg (group 2). The duration of myoplegia was 18.6 +/- 3.6 and 13.2 +/- 2.3 min, respectively. Clinically the relaxation was sufficient throughout the operation. Neuromuscular conduction recovered spontaneously in all cases, extubation was carried out 42.2 +/- 3.8 min after the last bolus injection of nimbex in group 1 and after 35.4 +/- 7.4 min in group 2. No appreciable fluctuations of hemodynamic parameters or other side effects (skin hyperemia or bronchial spasm) were observed during anesthesia. Studies of the benzyl isoquinoline myorelaxant cisatracurium besilate demonstrated that this effective and safe drug with an average duration of effect can be used in pediatric anesthesiology.
Agavelian
E G
EG
Arkharova
T B
TB
D000367:Age Factors; D000771:Anesthesia, Intravenous / Q000379:methods*; D001279:Atracurium / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology; D002648:Child; D002675:Child, Preschool; D005069:Evaluation Studies as Topic; D005260:Female; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D008297:Male; D009466:Neuromuscular Blocking Agents / Q000008:administration & dosage / Q000494:pharmacology*
D009466:Neuromuscular Blocking Agents; D001279:Atracurium; C101584:cisatracurium
Otsenka éffektivnosti novogo myshechnogo relaksanta nimbeksa (tsisatrakurium besilat) u deteĭ.